Literature DB >> 12574276

Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network.

N T Wetherall1, T Trivedi, J Zeller, C Hodges-Savola, J L McKimm-Breschkin, M Zambon, F G Hayden.   

Abstract

The increasing use of influenza virus neuraminidase (NA) inhibitors (NIs) necessitates the development of reliable methods for assessing the NI susceptibility of clinical isolates. We evaluated three NA inhibition assays against a panel of five clinical isolates each of influenza virus A/H1N1, A/H3N2, and B strains and four viruses with a defined resistance genotype (R292K, H274Y, R152K, and E119V). For fluorometric enzyme assay (FA) 1 (FA-1), 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid (MUNANA) at 100 microM was used as the substrate, with pretitration of the virus input. For FA-2, MUNANA at 200 microM was used as the substrate, with a fixed 1:10 dilution of input virus. For the chemiluminescence (CL) assay, the 1,2-dioxetane derivative of sialic acid at 100 microM was used as the substrate, with pretitration of the virus. Four different operators repeated the assays several times in a blinded fashion with both zanamivir and oseltamivir carboxylate (GS4071) to determine intra- and interassay variations. Mean 50% inhibitory concentration (IC(50)) values were lower and generally less variable with the CL assay. FA-1 displayed greater variation than the CL assay or FA-2 and the highest IC(50) values with zanamivir; FA-2 showed the highest values with oseltamivir, particularly for influenza virus B, and was more variable with zanamivir than was the CL assay. All three assays detected 40-fold or greater changes in IC(50) values for the resistant viruses with at least one drug. Mixing experiments, whereby increasing fractions (0, 20, 40, 60, 80, and 100%) of NA from a known NI-resistant virus were mixed with the corresponding NI-sensitive parental NA, indicated that the resolution of IC(50) values was clearer with the CL assay than with FA-2 for two of the resistant variants (R152K and E119V). The FA and CL methods were reliable for the detection of NI resistance, but all assays have certain limitations. Based on reproducibility, ease of automation, time required for the assay, and greater sensitivity, the CL assay was selected for future susceptibility testing of influenza virus isolates circulating globally.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12574276      PMCID: PMC149673          DOI: 10.1128/JCM.41.2.742-750.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir.

Authors:  R C Buxton; B Edwards; R R Juo; J C Voyta; M Tisdale; R C Bethell
Journal:  Anal Biochem       Date:  2000-05-01       Impact factor: 3.365

Review 2.  Resistance of influenza viruses to neuraminidase inhibitors--a review.

Authors:  J L McKimm-Breschkin
Journal:  Antiviral Res       Date:  2000-07       Impact factor: 5.970

3.  BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.

Authors:  Y S Babu; P Chand; S Bantia; P Kotian; A Dehghani; Y El-Kattan; T H Lin; T L Hutchison; A J Elliott; C D Parker; S L Ananth; L L Horn; G W Laver; J A Montgomery
Journal:  J Med Chem       Date:  2000-09-21       Impact factor: 7.446

4.  Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en.

Authors:  J L McKimm-Breschkin; T J Blick; A Sahasrabudhe; T Tiong; D Marshall; G J Hart; R C Bethell; C R Penn
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

5.  Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate.

Authors:  M Potier; L Mameli; M Bélisle; L Dallaire; S B Melançon
Journal:  Anal Biochem       Date:  1979-04-15       Impact factor: 3.365

6.  Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.

Authors:  J M Barnett; A Cadman; D Gor; M Dempsey; M Walters; A Candlin; M Tisdale; P J Morley; I J Owens; R J Fenton; A P Lewis; E C Claas; G F Rimmelzwaan; R De Groot; A D Osterhaus
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

7.  Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.

Authors:  L V Gubareva; L Kaiser; M N Matrosovich; Y Soo-Hoo; F G Hayden
Journal:  J Infect Dis       Date:  2001-01-11       Impact factor: 5.226

8.  Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution.

Authors:  J N Varghese; P M Colman
Journal:  J Mol Biol       Date:  1991-09-20       Impact factor: 5.469

Review 9.  Influenza virus neuraminidase inhibitors.

Authors:  L V Gubareva; L Kaiser; F G Hayden
Journal:  Lancet       Date:  2000-03-04       Impact factor: 79.321

10.  The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid.

Authors:  W P Burmeister; R W Ruigrok; S Cusack
Journal:  EMBO J       Date:  1992-01       Impact factor: 11.598

View more
  78 in total

1.  Genetic characteristics of 2009 pandemic H1N1 influenza a viruses isolated from Mainland China.

Authors:  Jiu-Ru Zhao; Yong-Dong Li; Li-Min Pan; Na Zhu; Hong-Xia Ni; Guo-Zhang Xu; Yong-Zhong Jiang; Xi-Xiang Huo; Jun-Qiang Xu; Han Xia; Na Han; Shuang Tang; Zhong Zhang; Zheng Kou; Simon Rayner; Tian-Xian Li
Journal:  Virol Sin       Date:  2011-12-10       Impact factor: 4.327

2.  Evaluation of three influenza neuraminidase inhibition assays for use in a public health laboratory setting during the 2011-2012 influenza season.

Authors:  William Murtaugh; Lalla Mahaman; Benjamin Healey; Heather Peters; Barbara Anderson; Mandy Tran; Marci Ziese; Maria Paz Carlos
Journal:  Public Health Rep       Date:  2013 Sep-Oct       Impact factor: 2.792

3.  Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir.

Authors:  M A Rameix-Welti; F Agou; P Buchy; S Mardy; J T Aubin; M Véron; S van der Werf; N Naffakh
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 4.  The threat of avian influenza A (H5N1). Part III: Antiviral therapy.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-04-12       Impact factor: 3.402

Review 5.  Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.

Authors:  Andrew J Burnham; Tatiana Baranovich; Elena A Govorkova
Journal:  Antiviral Res       Date:  2013-09-04       Impact factor: 5.970

6.  Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus.

Authors:  Maki Kiso; Tiago J S Lopes; Seiya Yamayoshi; Mutsumi Ito; Makoto Yamashita; Noriko Nakajima; Hideki Hasegawa; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2018-03-05       Impact factor: 5.226

7.  Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysis.

Authors:  Susu Duan; David A Boltz; Jiang Li; Christine M Oshansky; Henju Marjuki; Subrata Barman; Richard J Webby; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

8.  Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.

Authors:  Donald F Smee; Brett L Hurst; Min-Hui Wong; Kevin W Bailey; E Bart Tarbet; John D Morrey; Yousuke Furuta
Journal:  Antimicrob Agents Chemother       Date:  2009-11-09       Impact factor: 5.191

9.  Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa.

Authors:  Terry G Besselaar; Dhamari Naidoo; Amelia Buys; Vicky Gregory; Jo McAnerney; Jack M Manamela; Lucille Blumberg; Barry D Schoub
Journal:  Emerg Infect Dis       Date:  2008-11       Impact factor: 6.883

10.  Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08.

Authors:  Siri H Hauge; Susanne Dudman; Katrine Borgen; Angie Lackenby; Olav Hungnes
Journal:  Emerg Infect Dis       Date:  2009-02       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.